Crossmark

Are GLP-1 receptor agonists gerotherapeutics or just treatments for obesity?

Crossref DOI link: https://doi.org/10.1038/s43587-026-01165-4

Published Online: 2026-06-22

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Peyer, James G. https://orcid.org/0000-0001-8139-2517
License Information

Text and Data Mining valid from 2026-06-22

Version of Record valid from 2026-06-22
More Information

Article History

First Online: 22 June 2026

Competing interests

: J.G.P. is an executive of Cambrian Biopharma, Inc, which develops new drugs targeting key pathways in aging biology.